The Question
In 2023, opioid overdoses killed about 83,000 Americans — far more than died in car crashes. Deaths have since fallen sharply, to about 55,000 in 2024, but the toll remains enormous. Meanwhile, about one in four US adults — 24.3% in 2023, according to the CDC — lives with chronic pain lasting months or years, and for decades medicine's default answer was the same pill. Something is clearly broken.
Our prediction is specific: by 2032, non-opioid treatments will become the default first choice for chronic pain in most wealthy healthcare systems. We put the probability at 72%. The starting gun fired in January 2025, when the FDA approved the first genuinely new kind of pain drug in over two decades. But new drugs take time to spread — historically 8 to 12 years from approval to widespread use. The revolution is real. Whether it reaches patients fast enough is what this analysis is built to answer.
What the Evidence Shows
"Today's approval is an important public health milestone in acute pain management."
— Jacqueline Corrigan-Curay, acting director, FDA Center for Drug Evaluation and Research, January 2025In January 2025, the FDA approved a drug called suzetrigine — brand name Journavx. What makes it different from every painkiller that came before? It targets a single type of channel in pain-sensing nerve cells, called Nav1.8, without touching the brain's broader reward system. Opioids work by flooding the brain with signals that dull pain but also trigger euphoria, dependence, and, in too-high doses, stopped breathing. Suzetrigine sidesteps all of that. In phase 3 trials after surgery, it relieved pain better than placebo and about as well as a common hydrocodone-acetaminophen combination, without the addiction risk. But it is approved only for acute pain; trials in chronic nerve pain, such as diabetic peripheral neuropathy, are still under way.
That's not the only frontier. Spinal cord stimulation — a small device implanted near the spine that sends gentle electrical pulses to interrupt pain signals — can substantially reduce pain for some patients who've tried everything else. Wearable versions are bringing the same idea to the market without surgery. And AI-assisted pain mapping, using brain scans and machine learning to identify individual "pain fingerprints," is moving from labs toward clinics. Doctors might soon be able to see your pain rather than ask you to score it from one to ten.
We can sequence a genome in hours. Why are we still rating pain on a scale of one to ten?
Then there's the psychedelic frontier. Ketamine — a form of which, esketamine, is FDA-approved for treatment-resistant depression — is used off-label for conditions like complex regional pain syndrome, a nerve disorder so severe patients have described it as feeling like their limb is on fire. Psilocybin (the active ingredient in magic mushrooms) is being studied in small trials for hard-to-treat conditions such as cluster headaches. Neither is a mass-market solution yet. But they represent a fundamental shift in how scientists think about pain — less as a signal from the body, and more as something the brain is actively constructing.
Why This Is Happening
The financial case for change is overwhelming. A landmark Institute of Medicine report estimated that chronic pain costs the US $560 billion to $635 billion a year in treatment and lost productivity. That dwarfs the cost of developing any new drug or device. Employers and insurers have powerful financial reasons to want better options, and that pressure is now flowing into research budgets.
The opioid backlash has created a treatment vacuum. Stricter prescribing rules — introduced after the overdose crisis — have pushed many doctors to cut back on opioids dramatically. That's saved lives. It's also left millions of chronic pain patients without adequate treatment, tapering off drugs they depended on with no alternative offered. New non-addictive options would give doctors the confidence to treat pain aggressively again — without fear of creating the next crisis.
Pain science itself has been transformed. We now know that chronic pain isn't just an injury that won't heal. It involves real changes in how the brain is wired — the nervous system essentially learns to keep the alarm ringing even after the original cause is gone. Trauma, stress, and adverse childhood experiences can all amplify pain signals in measurable ways. That opens up entirely new approaches: not just numbing the signal, but reprogramming the system sending it.
What Could Happen
Suzetrigine and follow-on Nav1.8-blocking drugs reach broad clinical use by 2028. Major insurers cover spinal cord stimulation across high-income markets. Psilocybin earns FDA approval for specific pain conditions by 2030. By 2032, doctors treat chronic pain with personalised combinations of drugs, devices, and psychological therapy — the way HIV went from death sentence to manageable condition. Wealthy patients benefit first. But opioids are no longer the automatic first prescription.
Psychedelic-assisted therapies reach mainstream clinical use faster than expected, ahead of new drug classes. Wearable neurostimulation devices fall below $500 by 2029, enabling at-home pain treatment at scale. The transformation happens through technology and psychedelics first, with new pharmaceuticals playing catch-up.
The clinical trial results don't hold up in the real world. Suzetrigine works well for short-term post-surgical pain but proves less effective for the complex, long-term pain most chronic sufferers actually experience. Psilocybin trials hit regulatory walls. By 2035, pain medicine is still caught between over-reliance on opioids and undertreating patients — and tens of millions of Americans are still waiting for a real answer.
What Can We Do
You don't have to wait for new drugs. The evidence for non-opioid approaches is already strong — it's just underused. Regular low-impact exercise, like walking or swimming, is among the best-supported treatments for many kinds of chronic pain, and the CDC's 2022 guideline recommends trying non-opioid options first. It works partly through the body's own painkilling chemicals, and partly by reversing some of the nervous-system changes that keep pain alive. Sleep matters too. Poor sleep makes pain worse — it literally lowers your pain threshold — and a type of therapy called CBT-I (cognitive behavioural therapy for insomnia) can break that cycle without medication.
If your pain has roots in trauma or stress — and research increasingly suggests it often does — standard physical treatments may not be enough on their own. Pain psychologists, still rare in most healthcare systems, can help address the psychological dimension that physical medicine alone misses. Asking your doctor about a referral is worth trying, even if access is limited.
At the policy level, the gap is stark. Pain research receives a small fraction of the federal research money spent on diseases like cancer, even though chronic pain affects far more people. Closing that gap would accelerate the therapies already in development and build the evidence base to ensure they reach everyone equally — not just those who can afford new branded drugs out of pocket.
- CDC NCHS — "Chronic Pain and High-impact Chronic Pain in U.S. Adults, 2023" (Data Brief 518)
- CDC NCHS — "U.S. Overdose Deaths Decrease Almost 27% in 2024," May 2025
- FDA — "FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain," January 2025
- Suzetrigine for moderate-to-severe acute pain: two phase 3 randomized clinical trials (PMC)
- CDC — Clinical Practice Guideline for Prescribing Opioids for Pain, 2022
- Institute of Medicine — "Relieving Pain in America," 2011